A Phase 4 interventional study of Placebo and Melatonin in Schizophrenia, Schizoaffective Disorder and Bipolar Affective Disorder, sponsored by Lone Baandrup. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Lone Baandrup · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Schizophrenia with a site in Denmark — 10 open to participants now, 12 under way, none of them phase 3. Schizophrenia · Denmark.
Among the 79 studies in Schizophrenia with a site in Denmark, this one is the 39th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2011, is one of 12 in phase 4, and was the 33rd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →10 of the 79 studies in Schizophrenia with a site in Denmark are open now. Recruiting first, the newest first:
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 35–75
Nikolai Albert · Sites in Denmark
Ages 18–35
Anders Fink-Jensen, MD, DMSci · Sites in Denmark
Ages 18–70
Ole Köhler-Forsberg · Sites in Denmark
Ages 18–35 · Healthy volunteers
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 18–35
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 108 across the 67 interventional studies, 203 across the 11 observational. Of the 61 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 79 have an industry lead sponsor. The 10 most frequent:
Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Lone Baandrup has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
4 of the studies in Schizophrenia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07716969Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalTOPUS - Testing an Implemented Intervention to Reduce Duration of Untreated Psychosis | 2026-12-31 |
| NCT06431009University of AarhusThe Danish Region Midt Schizophrenia Cohort | 2026-12-31 |
| NCT07082777University of AarhusRecovery in Telling Life Stories | 2027-04-01 |
| NCT07404085Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalEpigenetic Enhancement of Cognitive Training in Aging Mood and Schizophrenia Spectrum Disorder Populations | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 79 studies in Schizophrenia with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia. Furthermore, researchers will investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.
Treatment of schizophrenia frequently includes prolonged administration of benzodiazepines despite lack of evidence of its use. It is often difficult to discontinue use of benzodiazepines because of development of dependence.
After being randomized to prolonged-release melatonin (Circadin®) 2 mg daily versus matching placebo, participants are required to slowly taper off their benzodiazepine dose towards no intake. Data are collected at baseline and at 6 months follow-up regarding medical treatment, cognition, psychophysiology, sleep, laboratory tests, adverse events, psychopathology, social function, and quality of life. Data on medical treatment, cognition, adverse events, social function, and quality of life are also collected at 2 and 4 months follow-up.
The results from this trial will assess if melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients. This group of patients is difficult to treat and therefore often subject to polypharmacy which may play a role in the reduced life expectancy compared to the background population. In addition, the data of the trial are also analyzed as an observational cohort design to investigate the association of benzodiazepine dose reduction/discontinuation with psychophysiology, cognition, sleep, quality of life, and other selected variables (not further described below, see trial protocol). Knowledge of these important clinical aspects is lacking in this group of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Melatonin
Drug: Placebo
Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
Also known as: Prolonged-release melatonin, Circadin®
Benzodiazepine (including benzodiazepine related drugs) dose at 6 months follow-up.
The general linear model is used with the outcome measure (dose after 6 months) as the dependent variable and the indicator of intervention and the baseline value as the independent variables. If the assumptions of the model cannot be fulfilled either directly or after transformation a non-parametric method will be used.
Time frame: 6 months follow-up.
Pattern of benzodiazepine dose over time.
The mixed model with repeated measures will be used to analyze the time course. The model is outcome measure = int + baseline + a\*t + b\*t\*t + c\*baseline\*t + d\*baseline\*t\*t + e\*I + f\*I\*t + g\*I\*t\*t where t is time, I the intervention indicator, int the intercept, and a through g the coefficients. Using Akaike's criterium the best co-variance matrix is first chosen among an unstructured, a compound symmetric, or a first order autoregressive.
Time frame: 2, 4, and 6 months.
The fraction of participants who has completely discontinued benzodiazepines 6 months after initiating trial medication.
The analysis will be done using a logistic regression model where logit(p) is the dependent variable, p is the probability of completing the withdrawal, and a binary intervention indicator is the independent variable.
Time frame: 6 months follow-up.
Pattern of P300 amplitude (psychophysiology) over time.
The mixed model with repeated measures will be used to analyze the time course. The model is outcome measure = int + baseline + a\*t + b\*t\*t + c\*baseline\*t + d\*baseline\*t\*t + e\*I + f\*I\*t + g\*I\*t\*t where t is time, I the intervention indicator, int the intercept, and a through g the coefficients. Using Akaike's criterium the best co-variance matrix is first chosen among an unstructured, a compound symmetric, or a first order autoregressive.
Time frame: 2, 4, and 6 months.
Pattern of Brief Assessment of Cognition in Schizophrenia (BACS) composite score over time.
The mixed model with repeated measures will be used to analyze the time course. The model is outcome measure = int + baseline + a\*t + b\*t\*t + c\*baseline\*t + d\*baseline\*t\*t + e\*I + f\*I\*t + g\*I\*t\*t where t is time, I the intervention indicator, int the intercept, and a through g the coefficients. Using Akaike's criterium the best co-variance matrix is first chosen among an unstructured, a compound symmetric, or a first order autoregressive.
Time frame: 2, 4, and 6 months.
Sleep efficiency (polysomnography) at 6 months follow-up.
The general linear model is used with the outcome measure (sleep efficiency) as the dependent variable and the indicator of intervention and the baseline value as the independent variables. If the assumptions of the model cannot be fulfilled either directly or after transformation a non-parametric method will be used.
Time frame: 6 months.
Pittsburgh Sleep Quality Index (PSQI) global score at 6 months follow-up.
The general linear model is used with the outcome measure (PSQI) as the dependent variable and the indicator of intervention and the baseline value as the independent variables. If the assumptions of the model cannot be fulfilled either directly or after transformation a non-parametric method will be used.
Time frame: 6 months.
Pattern of Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ-2) score over time.
The mixed model with repeated measures will be used to analyze the time course. The model is outcome measure = int + baseline + a\*t + b\*t\*t + c\*baseline\*t + d\*baseline\*t\*t + e\*I + f\*I\*t + g\*I\*t\*t where t is time, I the intervention indicator, int the intercept, and a through g the coefficients. Using Akaike's criterium the best co-variance matrix is first chosen among an unstructured, a compound symmetric or a first order autoregressive.
Time frame: 2, 4, and 6 months.
The record gives a start of Oct 2011, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
Lone Baandrup